KIF6 Trp719Arg genotyping (coverage policy)
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governing coverage of genetic testing for the KIF6 Trp719Arg variant to predict cardiovascular risk or statin response for Blue Cross and Blue Shield of Kansas members.
No material clinical or coverage changes in this revision.
Coverage Determination
Not covered — Experimental / Investigational
Coverage stance from policy
Refer to the member's contract benefits for individual coverage determinations.
Overall Coverage Rationale
Summary findings relevant to coverage decisions
See Section Summary: Clinically Valid (chunks 32, 38).
See Chain of Evidence and Section Summary: Clinically Useful (chunks 36, 37, 38).
Overall coverage stance
Not covered / insufficient evidence
No prospective RCTs have demonstrated improved outcomes from testing (chunk 38); clinical utility cannot be inferred when clinical validity is conflicting (chunk 36).
KIF6 genotyping is excluded from coverage because it is considered experimental / investigational for the purpose of predicting cardiovascular risk or the effectiveness of statin therapy. Providers should refer to the member's contract benefits at the time of service to determine coverage for an individual member.
There is no evidence that use of KIF6 testing to guide clinical management reduces the risk of coronary artery disease. The policy review concluded that the clinical utility has not been established: available studies include secondary analyses and a nonrandomized trial with methodological limitations, and no prospective randomized trials demonstrate that testing leads to management changes that improve outcomes.
KIF6 genotyping is considered experimental / investigational for all diagnoses related to this policy. This designation applies regardless of the specific clinical indication.
Testing for the KIF6 Trp719Arg variant is not considered medically necessary because the evidence is insufficient to demonstrate clinical utility in predicting coronary artery disease risk or guiding statin therapy decisions.
Clinical validity of KIF6 Trp719Arg testing is uncertain due to conflicting study results, and because clinical validity is a prerequisite for clinical utility, the lack of consistent validity evidence means the testing has not demonstrated benefit for patient care. Therefore, the policy does not support routine use of KIF6 testing.
Overall, testing for the KIF6 Trp719Arg variant is considered investigational / experimental and not medically necessary given inconsistent associations with CAD risk, mixed findings on statin response, and absence of trials showing improved clinical outcomes from testing-directed management.
Indications Considered
None established — potential utility considered
Potential uses considered but not proven
Described as potential clinical utility but not established (chunk 33).
Section summaries note uncertainty in validity and utility and absence of prospective RCT evidence (chunks 37, 38).
Services Not Covered
KIF6 genotyping for the purpose of predicting cardiovascular risk or informing statin therapy decisions is considered experimental / investigational and is therefore not covered under this policy.
Genetic testing for the KIF6 Trp719Arg variant (including Trp719Arg / 719Arg status) to guide initiation, intensification, or selection of statin therapy or to assess coronary artery disease risk has not demonstrated clinical utility and is not covered.
KIF6 testing is considered experimental / investigational for all diagnoses related to this policy and is therefore not covered for any diagnostic indication addressed by the policy.
Procedure and Diagnosis Codes
| 81479 | Unlisted molecular pathology procedure |
| Diagnosis | Experimental / investigational for all diagnoses related to this policy. |
Provider Actions and Billing Guidance
Predetermination / Benefit Verification
State and federal mandates and member contract language take precedence. Verify member benefits and predetermination requirements prior to testing. Contact Blue Cross and Blue Shield of Kansas Customer Service or submit a predetermination request for coverage determination or if there are questions about coverage.
- Predetermination recommended — member contract language and plan provisions govern coverage; submit prior to testing when coverage is uncertain.
- If no claims are being received for the service (archived), contact BCBSKS customer service or submit a predetermination request for current guidance.
- Verify benefits at time of service; predetermination/patient inquiry advised for questions about coverage or claims submission.
Coding and Potential Denial Risk
KIF6 genotyping is considered experimental / investigational for predicting cardiovascular risk and/or the effectiveness of statin therapy. Coding is informational only; inclusion of codes does not imply coverage and may present a denial risk if rendered for services considered investigational.
- Denial risk: KIF6 genotyping = experimental / investigational for all diagnoses related to this policy.
- Coding informational only — refer to member contract benefits in effect at time of service to determine coverage.
- If submitting claims, be aware payer may deny as investigational despite use of listed codes.
Suggested Documentation from Trial
Suggested documentation when KIF6 testing is performed in a study or trial context: include test (genotyping) results and evidence of any subsequent changes in management, such as statin prescriptions and fill records, and documentation of genetic counseling if performed.
- Include genotype test report (variant status) and laboratory report.
- Document statin prescription orders and pharmacy fill/adherence records to support any management changes attributed to testing.
- Include notes on genetic counseling or patient education if provided (informational; not an active requirement).
Provider Action — Predetermination / Patient Inquiry
Provider action note: Predetermination/patient inquiry — contact BCBSKS customer service or submit a predetermination request for coverage determination and updates when claims are not being received or policy is archived.
- Submit predetermination when testing is planned and coverage is uncertain.
- Use customer service or professional relations representative for questions about coverage or claims.
Provider Action — Benefit Verification
Provider action note: Verify member contract benefits and predetermination requirements prior to testing; member contract language takes precedence over policy language.
- Confirm benefits at time of service.
- If covered under a different BCBS plan, refer to that plan's medical policies.
Provider Action — Genetic Counseling (Informational)
Provider action note: Historical policy guidance mentions genetic counseling as informational; include counseling documentation when provided but note this is not an active coverage requirement.
- Document genetic counseling if performed.
- Genetic counseling reference is informational from prior policy revisions.
Clinical and Technical Background
Kinesin-like protein 6 (KIF6) is a member of the kinesin superfamily involved in intracellular transport; its precise biological role in atherosclerosis is unclear. The variant most commonly studied is the single-nucleotide polymorphism Trp719Arg (rs20455), which classifies individuals as carriers or noncarriers of the 719Arg allele. Epidemiologic and trial-based studies have produced mixed results regarding associations between this variant and coronary artery disease risk or differential response to statin therapy, and about 60% of the population carry the 719Arg allele in published reports.
Definitions and Acronyms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.